Therapy Detail

Therapy Name MVAp53
Therapy Description

MVAp53 is a modified vaccinia virus Ankara-based vaccine that may induce a T-cell mediated immune response against p53-expressing tumor cells (PMID: 21843052).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MVAp53 p53MVA p53 Vaccine 5 MVAp53 is a modified vaccinia virus Ankara-based vaccine that may induce a T-cell mediated immune response against p53-expressing tumor cells (PMID: 21843052).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 positive Advanced Solid Tumor sensitive MVAp53 Phase I Actionable In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02275039 Phase I MVAp53 Gemcitabine p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer Completed
NCT02432963 Phase I MVAp53 Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting